SBIR/STTR Research Award

Autoantibody and Autoantigen Biomarker Discovery Kits for the Research Community

Award identifier 3a10ea3c00fbf7f93788972a921ad9d312c40427ea2dfa4231982b3730d531d1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,190,560

Program and phase

SBIR · Phase II

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DIFFERENTIAL PROTEOMICS INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
CGL1UJU98GD5
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Immunoglobulins comprise 30-50% of human plasma proteins, and can show several- fold increased levels in many diseases. Natural autoantibodies, presumably part of an immune homeostasis mechanism, may comprise gt50% of a healthy individual's plasma. The differential identification of disease-associated antibodies must therefore be able to effectively subtract a large and idiosyncratic background component. Although autoantibodies and disease are important and well-studied, much work remains to be done in this area, which involves many diseases and potential applications. Proteomics researchers are increasingly involved in generating reliable reagents and in sharing them. This project will deliver a novel research tool for autoantibody and autoantigen biomarker discovery, to be provided for the scientific research community as a kit that incorporates Differential Capture Proteomics technology to subtract non disease-specific binding. This versatile kit will integrate proven modular and existing kit components with innovative methodologies, and will provide an experimentally straightforward but powerful tool to explore a wide range of antibody and antigen biomarker discovery projects. The Autoantibody and Autoantigen Biomarker Discovery Kit will therefore be offered to the Research Community in the hope that a two-way flow of ideas and reagents may contribute to such efforts in a variety of diseases involving autoantibodies. Specific Aim 1: Develop Kit Component 1, to isolate phage peptides binding disease-associated antibodies Specific Aim 2: Develop Kit Component 2, to isolate peptide beads binding disease-associated antibodies Specific Aim 3: Develop Kit Component 3, to isolate antibody beads binding disease-associated antigens PUBLIC HEALTH RELEVANCE: Although autoantibodies and disease are important and well-studied, much work remains to be done in this area, which involves many diseases and potential applications. This project will deliver a novel research tool for autoantibody and autoantigen biomarker discovery, to be provided for the scientific research community as a kit that incorporates Differential Capture Proteomics technology to subtract non disease-specific binding.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

6 SBIR/STTR records share this UEI (2007–2009). Reported award amounts total $2,465,303. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.